Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Mereo BioPharma Group plc (MREO)

1.3   -0.05 (-3.7%) 06-09 13:29
Open: 1.37 Pre. Close: 1.35
High: 1.38 Low: 1.26
Volume: 1,294,368 Market Cap: 162(M)

Technical analysis

as of: 2023-06-09 1:16:24 PM
Short-term rate:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Mid-term rate:       
Target: Six months: 1.63     One year: 1.9
Support: Support1: 1.1    Support2: 0.92
Resistance: Resistance1: 1.39    Resistance2: 1.63
Pivot: 1.14
Moving Average: MA(5): 1.21     MA(20): 1.16
MA(100): 1     MA(250): 1.01
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 77.5     %D(3): 64.8
RSI: RSI(14): 58
52-week: High: 1.85  Low: 0.49
Average Vol(K): 3-Month: 1,903 (K)  10-Days: 3,240 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ MREO ] has closed below upper band by 22.6%. Bollinger Bands are 57.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.4 - 1.41 1.41 - 1.41
Low: 1.21 - 1.21 1.21 - 1.22
Close: 1.34 - 1.35 1.35 - 1.36

Company Description

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

Headline News

Thu, 08 Jun 2023
Mereo BioPharma Group plc (MREO) Is A Lucrative Stock To Invest In. - Stocks Register

Wed, 07 Jun 2023
Mereo BioPharma Group plc - ADR (MREO) has fallen 0.87% Wednesday In Premarket Trading - InvestorsObserver

Tue, 06 Jun 2023
Should You Buy Mereo BioPharma Group plc - ADR (MREO) Stock on Tuesday? - InvestorsObserver

Tue, 06 Jun 2023
Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket - AgriFORCE - Benzinga

Tue, 06 Jun 2023
Coinbase, Apple stocks falls while GitLab, Thor shares rally, and other stocks on the move - MarketWatch

Tue, 06 Jun 2023
Mereo BioPharma Group (NASDAQ:MREO) Shares Down 0.9% - Defense World

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 125 (M)
Shares Float 79 (M)
% Held by Insiders 0 (%)
% Held by Institutions 51.6 (%)
Shares Short 5,160 (K)
Shares Short P.Month 3,900 (K)

Stock Financials

EPS -0.41
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.5
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -25.4
Return on Equity (ttm) -45.7
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.35
Qtrly Earnings Growth 0
Operating Cash Flow -39 (M)
Levered Free Cash Flow -23 (M)

Stock Valuations

PE Ratio -3.2
PEG Ratio 0
Price to Book value 2.55
Price to Sales 0
Price to Cash Flow -4.13

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.